We defied two distinct maturational compartments (proliferative and secretory) of osteogenic cells in vivo on the basis of ALP activity, BrdU incorporation, cell shape, and BSP production. BSP immunoreactivity was found to mark cells in the secretory but not in the proliferative compartment. We established the phenotypic similarity of primitive marrow stromal cells with proliferating perichondral cells (fibroblast-like, ALP' , BrdU', BSP-). This suggests the potential functional equivalence of the two cell types as committed non-secretory osteogenic cells and points to the duality of osteogenic cell compartments as a generalized feature of l
Introduction
Our ability to distinguish specific differentiative and maturational stages in the ontogeny of bone-forming cells in vivo has developed slowly. Classical studies based on following the fate of cells labeled by a pulse of [3H]-thymidine in vivo (24,26,27,34) have provided essentially all of our current understanding of osteoblast maturation in vivo. These studies showed that pre-osteoblasts in the cambial layer of the periosteum, matrix-forming osteoblasts, and osteocytes represent subsequent stages in the lifespan of osteogenic cells. The need to better understand how osteogenic cells may differ from one another functionally as they enter distinct compartments of differentiation and maturation has recently resulted in renewed attention to this topic (29). Indeed, pursuing the issue is important for at least two reasons: first, until specific phenotypes associated with subsequent stages of bone cell differentia-bone formation. We further showed that although BSP seaetion is a hallmark of the onset of osteogenesis, BSP antigenicity is lost both in osteoid and in a large proportion of mature osteoblasts during subsequent phases of bone deposition. This suggests that bone formation may not be a uniform event, as bone cells actually deposit antigenically, and likely biochemically, distinct matrices at specific times. ( J Histochem Cyrochem 41: [183] [184] [185] [186] [187] [188] [189] [190] [191] 1993) KEY WORDS: Bone sialoprotein: Alkaline phosphatase: Bromodeoxyuridine; Osteogenesis; Osteoblast differentiation. tion are defined, phenotypic identity expressed in specific cell lines cannot be conclusive; second, and more important, we need to know whether specific biosynthetic and/or regulatory functions are potentially accomplished by specific subsets of bone cells. This article addresses the definition of specific phenotypes within the osteoblast lineage in vivo. To this aim, we chose to look comparatively at three distinct features: (a) the expression of alkaline phosphatase activity, the major and most time-honored marker of osteogenic differentiation (26); (b) the expression of bone sialoprotein (BSP), an RGD-containing cell binding protein (13-17,19,22,23), which appears to represent a late feature in the development of the osteoblast phenotype (7,lO); and (c) the incorporation of the thymidine analogue bromodeoxyuridine (BrdU) as a marker of cells in S-phase (IJl), and therefore of cell proliferation. These were comparatively assessed at different stages of rat bone development.
Materials and Methods
Animals and Tissue Preparation Protocols. Pregnant albino Wistar rats were sacrificed by ether inhalation. Fetuses were collected at 12, 15, or 18 days of gestation, cut sagittally, and fmd in 4% formaldehyde (freshly made from paraformaldehyde) in 0.1 M phosphate buffer for 2 hr at 4°C. The material was left undecalcified and was processed for paraffin embedding or low-temperature glycol methacrylate (GMA) embedding (3.8). Paraffin sections were used for BSP immunocytochemistry and semi-thin GMA sections for enzyme cytochemistry. At least two fetuses for each gestational age were cut in their entirety into numbered serial sections, for histological assessment of the extent and progression of ossification in individual bones. Antisera to BSP. Two different rabbit antisera were used for localization of BSP. LF G (13) was raised against BSP extracted and purified from human developing bone. LF 87 (21) was raised against BSP produced by UMR-106-BSP, a rat osteosarcoma cell line. Both antisera recognized normal rat bone-derived BSP in dot-blot and Western blot assays. BSP Immunocytochemistry. BSP immunolocalization at the light microscopic level was carried out using an indirect immunoperoxidase protocol as described (7). Anti-BSP antisera were used at the dilution of 1:100 in PBS, 0.1% BSA. Peroxidase-labeled goat anti-rabbit IgG (Dako; Santa Barbara, CA) were used at the dilution of 1:50. Controls included omission of the first antiserum, replacement of the first antiserum with normal rabbit serum, and use of antisera pre-absorbed with human BSP (7).
Bromodeoxyuridine Labeling. BrdU labeling of fetal tissues was performed essentially as described (12). Briefly, 600 mglkg body weight BrdU dissolved in 1 mlO.9% saline was injected into the peritoneal cavity of another group of pregnant albino Wistar rats at Days 15 and 18 of gestation. Two hours after injection the animals (two for each gestational age) were sacrificed and the fetuses collected. Tissues were fixed in 4% formaldehyde in 0.1 M phosphate buffer, pH 7.2, and processed for paraffin embedding.
Immunohistochemistry of BrdU-labeled Tissues. A monoclonal antibody recognizing 5-bromo-2'-deoxyuride (clone BU-1) was purchased from Amersham (Poole, UK). The antibody was used undiluted and with no pre-treatment of the sections, since the reagent as supplied contains a nuclease-producing single-stranded DNA readily accessible to the antibody. Sections were first exposed to undiluted normal rabbit serum for 20 min, then incubated for 1 hr at room temperature with the anti-BrdU monoclonal. Sites of antibody binding were revealed with a biotinylated rabbit antimouse immunoglobulin antiserum (Dako) (1:200 in PBS, 0.1% BSA) and an avidin-biotin-horseradish peroxidase complex (Dako), diluted and used according to manufacturer's specifications. The DAB reaction was done according to Graham and Karnovsky (18) .
Alkaline Phosphatase Cytochemistry. ALP cytochemistry was done using a simultaneous coupling azo dye method (with naphthol-AS-phosphate as substrate and Fast Blue BB as coupler) adapted to semi-thin sections from GMA tissue blocks (3, 8) . Formulation of GMA and low-temperature processing were as described (3, 8) . To compare the patterns of ALP and BSP expression, sections from GMA blocks reacted for ALP were matched with corresponding paraffin sections immunostained for BSP, based on the preliminary assessment of morphology made on serial sections. Double Immunolabeling for BrdU and BSP. After inhibition of endogenous peroxidase, sections were exposed to undiluted normal swine serum for 30 min. Anti-BSP antiserum (LF6) was used at the dilution of 1:80 in PBS, 0.1% BSA. A peroxidase-labeled swine anti-rabbit IgG antiserum was used as the second layer. The DAB reaction was developed as usual. Endogenous alkaline phosphatase was inhibited with 1% levamisole. The anti-BrdU monoclonal was applied undiluted for 1 hr, followed by a rabbit anti-mouse IgG (Dako) (125.30 min), and mouse alkaline phosphatase-antialkaline phosphatase (APAAP) complex (Dako). Alkaline phosphatase was revealed with naphthol-AS-phosphate as substrate and Fast Blue BB as coupler (0.03% in 0.01 M Tris buffer, pH 8.7, 20 min at 37'C).
Combined ALP Cytochemistry and BrdU Labeling. We found that a fivation time of not longer than 1.5 hr and prolonged incubation in the alkaline phosphatase reaction medium (2.5 hr) resulted in satisfactory demonstration of enzyme activity in paraffin sections of rat fetuses. ALP-reacted paraffin sections from BrdU-labeled fetuses were used for combined ALP cytochemistry and BrdU labeling. ALP was performed first, with the incubation time indicated above, followed by thorough washing and BrdU immunocytochemistry performed as described above,
Results

Distribution of BSP in Rat Tissues
Whole embryo sections and sections of a variety of adult tissues and placenta were used for a preliminary survey of the distribution of BSP in the rat. Neither BSP immunoreactivity nor evidence of bone formation was seen in Day 12 fetuses. BSP immunoreactivity was restricted to skeletal tissues of Day 15 and 18 fetuses and to individual trophoblast cells in placenta (not shown), in agreement with previous studies of human tissues (7). Within skeletal tissues, reactivity was seen in osteoblasts and newly deposited, unmineralized, or partially mineralized bone matrix. In addition, we noted some staining of individual osteoclasts and of some hypertrophic chondrocytes in cartilaginous bone rudiments, again in agreement with previous studies on human tissues (7). These BSPpositive hypertrophic chondrocytes were located just underneath the perichondrium in rudiments where periosteal ossification
had not yet begun.
The general pattern of BSP immunoreactivity observed was the same in all bones. We could not identdj significant differences in the pattern of osteoblast and bone matrix staining in endochondral vs intramembranous ossification. When the orientation of the sectioning plane ran exactly perpendicular to the long-bone axis, a continuous thin layer of BSPpositive osteoid surrounded the cartilage rudiment. All osteoblasts adjacent to this layer displayed intracellular labeling for BSP (Figure 3) . osteoid and bone cells. BSP-positive cells, clearly much fewer than ALP-positive cells, were predominantly located in the interior of each rudiment (Figure 4b ), in association with growing bony trabeculae and forming primary Haversian systems. Since most of the osteoblasts lining the bone surfaces not only were ALP positive but also had features of typical "plump" mature osteoblasts, we concluded that only a fraction of such cells displayed BSP immunoreactivity. We also concluded that BSP immunoreactivity is observed in virtually all osteoblasts and in the associated osteoid at the beginning of bone deposition (as seen at Day 15) . but is lost in both cells and osteoid at formative sites where bone deposition has progressed beyond this initial point (as seen at Day 18).
ALP ana' BSP Expression in Osteogenic CeZh
B7dU Labeling of Osteogenic Cells
At Day 15, spindle cells (ALP+, BSP-) in the outer perichondral zone incorporated BrdU, whereas round cells in the internal zone (ALP+, BSP') did not (Figure sa) . Therefore, the two compartments of osteogenic cells identified in Day 15 perichondrium by morphology, ALP activity, and BSP immunoreactivity also differed in proliferative activity as assessed by BrdU labeling. At Day 18, a large number of BrdU-labeled cells were detected in the interior of invaded rudiments, i.e., at the site of endochondral ossification (Figure 5b ). BrdU-labeled cells were also seen at the sites of formation of primary Haversian systems within sub-periosteal bone. Here, as in the perichondriumlperiosteum, the BrdU-labeled cells were located next to the layer of secretory osteoblasts, in a perivascular position (Figure 5c ). To better identify the BrdU-positive cells in the forming marrow spaces and Haversian systems, we looked at paraffin sections that were double-labeled for either BSP and BrdU or ALP and BrdU. Cells labeled for BrdU were not labeled for BSP (Figure 6a) , except for very rare individual cells. BrdU-labeled cells were mostly located within the marrow spaces proper, often in a perivascular position. They displayed strong membrane-associated ALP activity, and exhibited the elongated or branched morphology of primitive reticular cells of the marrow stroma (Westen-Bainton) cells (33) (Figures 6b and 6c) . Very occasionally, cells labeled for both BrdU and ALP were also seen in direct contact with bone surfaces (Figure 6d ). We concluded that in the primitive marrow spaces, the duality of maturational compartments of osteogenic cells observed in the perichondriumlperiosteum was maintained. Primitive marrow stromal cells (reticular cells) were the marrow counterpart of fibroblast-like, ALP-positive, BrdUincorporating, BSP-negative perichondral pre-osteogenic cells.
Discussion
By means of the combined use of ALP cytochemistry, BSP immunocytochemistry, and BrdU labeling, we defined two distinct sets of phenotypic features, each associated with a specific maturational compartment of bone cells. Cells in both compartments exhibit high levels of ALP activity, which can be taken as evidence of their osteogenic commitment, but they differ remarkably in cell shape, BrdU incorporation, and BSP production.
One compartment is composed of ALP', BrdLJ+, BSP-fibroblastlike cells, whereas the second one is composed of ALP+, BrdU-, BSP+ cells with osteoblast morphology. On the basis of the demonstrated incorporation of BrdU into ALP-positive fibroblast-like cells of the perichondriumlperiosteum, these cells can be regarded as equivalent to those described earlier by Owen as thymidineincorporating pre-osteoblasts (24, 26, 27) . Owen's studies demonstrated that if chased for specific time intervals, [ 3H]-thymidinelabeled periosteal cells can be seen to traverse a maturational sequence whose subsequent stages are represented by spindle pre-osteoblasts, osteoblasts, and osteocytes. Therefore, we can reasonably hypothesize that the appearance of the ability to produce BSP marks the boundary between the pre-osteoblast and the osteoblast stage. Since BSP antigenicity as detected by light microscopy stems from the localization of the protein over secretory structures of the cell (Golgi and pro-secretory granules) (9), we can further specify that secretion of BSP marks the boundary between the two maturational compartments.
We have further shown that within the "mature" osteoblast compartment BSP secretion does not occur simultaneously in all cells. Therefore, not only does BSP secretion provide a major functional difference between osteoblasts and pro-osteoblasts, it also separates distinct functional stages among matrix-forming osteoblasts. We infer this from (a) the consistent BSP immunoreactivity observed in virtually all osteoblasts involved in the deposition of the first layer of perichondral bone, as well as in the osteoid they produce, and (b) the absence of BSP immunoreactivity in both osteoblasts and osteoid during subsequent bone deposition at each site. It fol- lows that bone formation is not a uniform process, and specific matrix microenvironments that differ with respect to BSP content are produced at specific times. The association of BSP secretion with the onset of bone formation is of interest if the cell binding properties of BSP (16,17.22.23,32) are taken into account. Proper adhesion, orientation, and polarization of cells competent for matrix deposition are necessary for bone formation to occur in such a highly spatially oriented fashion. The occurrence of BSP immunoreactivity in chondrocytes at the edge of cartilage rudiments before bone formation begins is also in keeping with this interpretation, and may suggest a direct cooperation of a subset of hypertrophic chondrocytes and osteoblasts in the very early stages of bone formation.
That bone matrix produced by osteoblasts can actually be different at different times and sites is an often overlooked fact, for which subperiosteal (plexiform) bovine bone provides a distinct major example (see 2 for review). The first layer of bone deposited in this tissue remains distinguishable from subsequently added bone as a sharp, hypermineralized line (Mittelinien). Biochemical analysis of microdissection samples of the Mittelinien and subsequently added bone demonstrated that the former are relatively enriched in non-collagenous protein and poorer in collagen, compared with the latter (28). We believe that our differential BSP immunoreactivity in "early" and "later" bone matrix can represent an equivalent phenomenon.
The existence of cells with osteogenic potential within the bone marrow is firmly established (see 25 for review), although the identity of osteogenic cells in the intact tissue and their position in the hierarchy of the stromal cell system have remained elusive. Classical histology has long indicated that the marrow stroma includes cells of periosteal origin which follow blood vessels at the time of rudiment invasion (20). We have shown that within forming marrow spaces a cell population with the same phenotypic properties as periosteal pre-osteoblasts (fibroblast-like, ALP', BrdU', BSP-) can be identified. These cells are noted for their branched morphology, are often seen in a perivascular position, and are located next to the layer of matrix-forming osteoblasts. The morphology, location, and ALP activity of these cells enable them to be identified as the alkaline phosphatase-positive "reticulum" cells described by Westen and Bainton (33), as observed in developing as opposed to postnatal marrow. Cells described as the in vivo target of parathyroid hormone in developing bone display the same mor-phology and alkaline phosphatase activity (30,31). Branched fibroblast-like stromal cells also occur in the human postnatal marrow ( 5 ) , are able to convert to adipocytes (6), and undergo changes in number and distribution in hyperparathyroidism (4). This emphasizes how defining the heterogeneity of maturational stages of bone cells in vivo might help to identdy the stage at which major regulatory events of bone formation and metabolism occur. We suggest that proliferating pre-osteogenic cells with fibroblast-like morphology and strong ALP activity, found in the perichondriumlperiosteum as "spindle pre-osteoblasts" and within marrow spaces as "reticular cells," may represent local modulations of the same cell type and maturational stage, which represent the direct reservoir of "effector" secretory osteoblasts, and may correspond to the target cells of more than one bone regulatory factor.
